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Cancer immunotherapy has recently emerged as the fourth treatment modality, in addition to
surgery, chemotherapy, and radiotherapy. These advances are the result of important discoveries in
the field of regulation of the immune response, especially on the mechanisms which turn “on” and
“off ” immune responses (1, 2). A diseasewhich has proved to be a canonicalmodel to test therapeutic
immunotherapy is the immunogenic cutaneous melanoma (3). So far, “passive” immunotherapy
with monoclonal antibodies has outpaced “active” immunotherapy with antitumor vaccines (4, 5),
and monoclonal antibodies which antagonize the “off ” responses have been recently introduced in
clinical practice (6, 7).
In this Research Topic containing nine articles, Aris and Barrio (8) present an updated review
of current immunotherapeutic strategies and their combinations with oncogene-targeted therapy
for cutaneous melanoma. Preclinical evidence, as well as emerging clinical results outlined in this
review, might represent potentially powerful tools for cancer treatment. Besides, several monoclonal
antibodies have been introduced into the clinic for cancer treatment. Among them, recently arrived
anti-chemokine receptor antibodies are presented in a review by Vela et al. (9). The authors discuss
the main achievements obtained with them to inhibit the interactions between cancer cells and
their ligands. These antibodies hinder the interactions between chemokine receptors and chemokine
signals delivered by different organs, thus preventing tumor cell survival, proliferation, adhesion, or
migration that could result in metastatic spreading.
In spite of these recent successes, many unresolved practical and theoretical clues remain to
be answered. The review by Madorsky Rowdo et al. (10) addresses relevant questions about the
identity of the lymphocytes that eliminate tumor cells, their entry into tumor microenvironment,
and parameters that could be used to determine the anti-tumor immune response. Also, the use
of cancer vaccines to increase the lymphocytic tumor infiltration and the multiplicity of antigens
that must be targeted to achieve significant clinical responses are discussed. Related to this issue, a
Clinical Case Study reported by Aris et al. (11) shows histological evidence of the recruitment of
immune cells induced by an anti-melanoma vaccine at the inoculation site, probably reflecting the
early steps of the afferent immune response. Moreover, antitumor vaccination has been extensively
developed in the last 15 years, even to target immune responses to hematologic tumors. Here, Di
Stasi et al. (12) present the results obtained in the clinic with a peptide vaccination strategy that
targets WT1 antigen in acute myeloid leukemia and myelodysplastic syndromes. Evidence of WT1-
specific T cells induction that correlates with progression-free survival has been shown in several
studies, encouraging further investigation to strengthen this cancer vaccination approach.
Regarding the development of adaptive antitumor immune responses, a basic assumption was
that infiltrating anti-tumor immune cells were educated to recognize tumor antigens in secondary
lymphoid organs, and were then recruited into the tumor microenvironment to exert anti-tumor
activity. Here, Germain et al. (13) present evidence, focusing on the B cell compartment, suggesting
that the immune response can also take place in tertiary lymphoid structures located in the areas of
chronic inflammation as well as in cancer.
Dendritic cells (DC) play a pivotal role on the orchestration of the immune responses and are thus
key targets in cancer vaccine design. In this Research Topic, three reviews address the role of DC in
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immunotherapy. First, recent findings in murine models regard-
ing the anti-tumoral mechanisms of DC-based vaccination are
reviewed by Mac Keon et al. (14). They focus on diverse issues,
such as the antigen sources, the use of adjuvants, DC maturing
agents, and the role of DC subsets in the antitumor response. In
the human setting, Pizzurro and Barrio (15) present the main hot
spots of the anti-tumor immune response, which are exploited
with different DC-based vaccine designs. They focus on the pro-
cesses taking place at the injection site, new adjuvants combi-
nations, as well as lymph nodes homing to activate naïve lym-
phocytes and generating effector cells, and immune memory to
control tumor growth. Finally, Pampena and Levy (16) discuss
the participation of natural killer (NK) cells as alternative immune
components that could cooperate in successful vaccination treat-
ment. This article addresses the NK cell antitumor action sites
and their role in DC-based cancer vaccines as determined by
immune-monitoring in preclinical and clinical settings.
With no doubt, cancer immunotherapy is now a treatment
modality that can change the reality for many cancer patients,
achieving prolongation of their metastasis-free and overall sur-
vival. Scientific research over the last 20 years supports a key
role of the immune system in the elimination of the disease,
opening new roads for combinatorial treatments to be tested
in the clinic. The contributions included in this Research Topic
have exposed current lines of investigation, where clinical suc-
cesses are recognized, but also a considerable lack of under-
standing of the mechanisms underlying such outcomes is also
perceived. More research in the field is warranted to fully exploit
the immune system as a therapeutic powerful tool for cancer
patients.
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